Mylan Ireland withdraws marketing authorisation application of Fingolimod Mylan

Following a decision from the European Medicines Agency that bioequivalence data were not considered adequate, and sufficient precautions to prevent the development of nitrosamines were not taken during manufacturing, the marketing authorisation application has been withdrawn.

Source:

European Medicines Agency